Rad51 protein plays a pivotal role in homologous recombination (HR), which is involved in double-strand break repair and in genome maintenance. Despite interactions with tumor suppressor proteins, the role of mammalian Rad51 and more generally of HR in tumor prevention is not clearly established. Indeed, both high and low frequencies of HR as well as high and low levels of RAD51 expression have been reported in tumors and in precancerous conditions. To address the question of the impact of HR on tumorigenesis, we used Chinese hamster ovary (CHO) p53-defective cell lines overexpressing the mouse MmRAD51, which stimulates HR (we name these lines: Hyper-rec lines). In parallel, we used CHO cell lines expressing a RAD51 dominant-negative form that specifically inhibits gene conversion without affecting cell viability (Hypo-rec lines). These different lines were injected into nude mice to measure their tumorigenicity. Hypo-rec lines generated a higher frequency of tumors, which also exhibited faster growth, compared to control and Hyper-rec lines. Consistent with tumorigenicity, Hypo-rec cells exhibit spontaneous centrosome duplication defects and aneuploidy. These results are the first direct evidence of involvement of RAD51 in tumor repression.
Introduction
Homologous recombination (HR) is a fundamental process controlling genome stability. Rad51 protein, which is conserved from bacteria to mammals, plays a key role in HR (Morita et al., 1993; Shinohara et al., 1993) . Mammalian RAD51 controls double-strand break (DSB) repair mediated by gene conversion (Lambert and Lopez, 2000) and is also in part involved in sister-chromatid exchange (Lambert and Lopez, 2001) .
Despite interactions with tumor suppressor proteins (Sturzbecher et al., 1996; Buchhop et al., 1997; Mizuta et al., 1997; Scully et al., 1997) , the role of mammalian Rad51 in tumor prevention is not directly established, as discussed previously .
Contrasting results connecting RAD51 and tumorigenesis have been reported in the literature. Indeed, both increase and decrease in HR have been shown in tumor cells and in conditions of cancer predisposition. Inactivation of the tumor protection genes BRCA1 or BRCA2 or overexpression of the oncogene Bcl-2 predisposes to cancer and leads to a defect in HR (Moynahan et al., 1999 Saintigny et al., 2001b) . However, mutations in any of these genes has pleiotropic effects on cell cycle, transcription, apoptosis, chromatin, and other repair systems, each of them being able to explain the oncogenic phenotype. In contrast, stimulation of HR has been described in Bcl-x(L) overexpressing lymphoblastoid cell lines (Wiese et al., 2002) or in cells devoid of ATM or of p53, corresponding also to cancer predisposition phenotypes (Meyn, 1993; Wiesmuller et al., 1996; Bertrand et al., 1997; Mekeel et al., 1997; Saintigny et al., 1999) . Moreover, decreased levels of Rad51 have been noted in breast carcinomas (Yoshikawa et al., 2000) , whereas increased levels of Rad51 protein have been described in other cancer cells (Maacke et al., 2000; Raderschall et al., 2002) and in cells expressing the oncogenic kinase BCR-ABL (Slupianek et al., 2001) . Mutations in DSB repair genes, among them RAD51, have been described in tumors, but the impact of these mutations on both HR and tumorigenesis remains to be established . Consequently, in this somewhat confusing situation, the question arises on the actual role of RAD51 in tumorigenesis. To address these questions, we overexpressed the wild-type mammalian MmRAD51 in Chinese hamster ovary (CHO) cells and measured its impact on tumor development after injection in nude mice. In parallel, we used CHO cells expressing a RAD51 dominant-negative form (SMRAD51) that specifically inhibits HR, without affecting cell viability or cell growth (Lambert and Lopez, 2000) . Since the knock out of the RAD51 gene leads to cell lethality in the mouse and in the chicken DT40 line, these CHO cell lines represent a rational tool and an opportunity to analyse the impact of the alteration of the RAD51 pathway in living mammalian cells.
Results

Cell lines used
All the cell lines used were derived from the same parental hamster CHO-DRA10 cell line (Liang et al., 1998) . This line has been transfected with an empty expression vector (C3 and C4 cell lines) or with the same expression vector containing either the wild-type mouse MmRAD51 cDNA or a chimeric SMRAD51 coding for the 55 N-terminal amino acids from the yeast ScRad51 protein fused to the entire mouse MmRad51 protein.
Overexpression of wild-type mammalian Rad51 protein in these CHO cell lines has been shown to stimulate spontaneous HR as well as HR induced by a variety of genotoxic stresses, including ionizing radiation, replication (elongation) inhibitors, and an alkylating agent such as MNU Lopez, 2000, 2001; Saintigny et al., 2001a) . SMRAD51 inhibits spontaneous as well as gene conversion induced by ionizing radiation, hydroxyurea, MNU, UV-C, in a dominantnegative manner, without affecting cell viability (Lambert and Lopez, 2000 Saintigny et al., 2001a) . Lines overexpressing the wild-type MmRAD51 are defined as Hyper-rec lines, whereas the lines expressing SMRAD51 are defined as Hypo-rec lines. The names of the different cell lines and their status for HR are summarized in Figure 1a . Examples of overexpression of MmRAD51 or SMRAD51 are shown in Figure 1b .
Importantly, CHO are mutant p53 cells (Hu et al., 1999) and we never succeed in expressing the dominantnegative SMRAD51 in wild-type p53 cells, suggesting that the essential role of RAD51 is dependent on the p53 status (data to be published). However, the different cell lines used here, exhibit similar growth kinetics ( Figure 1c ) and allows to measure the impact of RAD51 pathway defect in a p53 À background.
Hypo-rec cells show centrosome fragmentation abnormalities and aneuploidy
Centrosome and ploidy defects have been observed in CHO cell lines mutant for XRCC2 or XRCC3, two Rad51 paralogs (Griffin et al., 2000) , suggesting the impact of the HR pathway on this process. However, RAD51 itself has not been evaluated on these processes. We thus determined here whether in Hypo-rec cells these phenomena are affected. Since RAD51 is involved in DSB repair and in ionizing radiation-induced HR (Lambert and Lopez, 2000) , we asked as to whether RAD51 affects centrosome fragmentation with or without radiation. We first measured centrosome fragmentation in the different cell lines, by immunocytofluorescence using a g-tubulin antibody (Figure 2a and b) . The CHO cells are defective for p53 and consistently exhibit centrosome fragmentation abnormalities. However, a statistically higher occurrence of centrosome fragmentation was recorded in the Hypo-rec cell lines whether or not the cells were irradiated (Figure 2c ): the rate of normal mitosis with two centrosomes was lower in the two Hypo-rec lines and, in parallel, the rate of abnormal mitosis with three centrosomes was twofold higher in the two Hypo-rec lines. A Mann-Whitney test indicated a higher number of centrosomes in the Hypo-rec lines, with statistically different distributions (P at least o0.02) (Figure 2c ). These results show an increase in centrosome fragmentation in the Hypo-rec cells, over the background resulting from the p53 alteration. Since centrosome defects should lead to aneuploidy, we measured the ploidy of nonirradiated cells prior to injection (Figure 3 ). While ploidy was similar in control and in Hyper-rec cells, significantly more aneuploid cells appeared in the Hypo-rec cell population. In Hypo-rec cells, we observed a strong increase of metaphases with 20 or 21 chromosomes (corresponding to loss of chromosomes) and also metaphases with more than 22 chromosomes per metaphase (corresponding to gain of chromosomes) (Figure 3 , right panels). Thus, this aneuploidy corresponds to both, gains and losses of chromosomes and is consistent with the increase in centrosome fragmentation in the Hypo-rec cells. Since many tumors are associated with centrosome defects, which result in aberrant chromosome segregation and thus in loss or gain of chromosomes (Lengauer et al., 1998; Pihan et al., 1998) , we then verified as whether SMRAD51 affects tumorigenesis.
Defect in the RAD51 recombination pathway stimulates tumorigenesis
To measure the impact of the expression of the different RAD51 forms on tumorigenesis, we injected the cell lines described in Figure 1 in athymic nude mice, and measured the appearance and development of tumors. We measured tumor occurrence and tumor growth after injection of two independent Hypo-rec, two independent Hyper-rec, and two independent control cell lines. Consistently, the two cell lines of each category behaved identically in terms of both tumor occurrence and tumor growth (Figures 4 and 5) .
Injection of the CHO parental lines results in tumor formation, consistent with their p53 status (Hu et al., 1999) . However, in a similar background, expression of SMRAD51 significantly increased the efficiency of tumor formation with both lines tested (Figure 4) . A plateau was reached 15 days after injection, and the mean rates of tumor induction at Day 20 were 46.5 and 36.5% with the control and Hyper-rec lines, respectively, whereas this rate increased to 85.5% with the Hypo-rec lines (Figure 4) . The w 2 test indicated statistically significant differences between Hypo-rec À cell lines used here. To estimate the growth of tumors, we measured their sizes (Figure 5a ). Tumor growth was calculated for the first 12 days after tumor diagnosis (Figure 5b ), corresponding to a period of 17-22 days after injection. Indeed, tumors appear 5-10 days after injection and tumor growth was then measured. This corresponds to the actual growth period because after 12 days, autopsy showed foci of necrosis in most of the tumors, which could modify their size. The linear regression curves of tumor size dispersions show that the slopes of the two Hypo-rec tumor sizes are greater than those of tumors from the two control and the two Hyper-rec lines (Figure 5b ). This indicates a faster tumor growth for the Hypo-rec cells. Interestingly, the two lines for each category (the two controls and two Hyper-rec, and two Hypo-rec) exhibited comparable tumor growth. Analysis of covariance (Sokal and Rohlf, 1995) indicates that the slopes differ significantly (Po0.05). These data indicate an accelerated tumor growth of Hypo-rec cells, which are affected in the RAD51 recombination pathway.
Discussion
In the present experiments, the overexpression of the wild-type MmRAD51, which stimulates both spontaneous and induced recombination, does not stimulate tumorigenesis. Increase in recombination has been described in different conditions associated with a cancer predisposition such as cell lines from ataxia telangiectasia patients (Meyn, 1993) , p53 À -defective cells (Wiesmuller et al., 1996; Bertrand et al., 1997; Mekeel et al., 1997; Saintigny et al., 1999) and cell lines expressing the oncogenic kinase BCR/ABL (Slupianek et al., 2001 ). More specifically, high levels of Rad51 protein have been described in cancer cells (Maacke et al., 2000; Slupianek et al., 2001; Raderschall et al., 2002) . The increase in recombination associated with the tumor predisposition cases described above could thus be an indirect consequence of another different primary defect. For instance, since Rad51 is cell cycle regulated and is mainly expressed in late S/G2 phase (Flygare et al., 1996; Yamamoto et al., 1996; Chen et al., 1997) , it should be expressed in proliferating cells. Consequently, the level of Rad51 could reflect a high proliferation rate. Alternatively, the p53 mutation may overwhelm and mask the putative tumorigenic effect of the overexpression of a wild-type mammalian RAD51.
In a symmetrically opposite way, expression of the dominant-negative SMRAD51 gives rise to centrosome fragmentation, aneuploidy and stimulates tumorigenesis. It may be objected that the chimeric SMRAD51 could affect another pathway possibly different from HR but responsible for the increase in tumorigenesis. This is unlikely for several reasons. First, among the different DSB repair processes, SMRAD51 affects gene conversion and does not affect nonhomologous endjoining or single-strand annealing (Lambert and Lopez, 2000) . This shows the high specificity of SMRAD51 for gene conversion, as expected for a specific dominantnegative RAD51. This also implies that the putative additional pathway, possibly affected by SMRAD51, Figure 4 Time-course of tumor appearance. The number of injected animals is indicated in parentheses beside the corresponding cell line name. SMRad51-1 and SMRad51-2 correspond to two independent Hypo-rec lines expressing the dominant-negative SMRAD51; MmRad51-2 and MmRad51-2 are two independent Hyper-rec cell lines (Lambert and Lopez, 2000) ; C3 and C4 are two independent control cell lines Kinetics of tumor growth for each cell line. 0 corresponds to the day of diagnosis (5-10 days after injection). The linear regression models for each cell line are indicated in each panel and were tested by ANOVA (Po0.0001 for SMRad51-1, SMRad51-2, C3, and MmRad51-2 lines; P ¼ 0.02 for C4; P ¼ 0.04 for should affect neither nonhomologous end-joining nor single-strand annealing. Second, the only phenotype observed when SMRAD51 is expressed is HR inhibition, and this affects neither proliferation nor cell cycle distribution, spontaneous viability and sensitivity to a variety of stresses, including ionizing radiation, UV-C, MNU, replication elongation inhibitors. Alteration of another pathway that could lead to tumorigenesis would probably affect at least one of these phenotypes. Third, SMRAD51 and wild-type RAD51 act in symmetrically opposite ways on HR, suggesting that the impact of SMRAD51 on tumor occurrence results from inhibition of the RAD51 pathway. Fourth, spontaneous centrosome fragmentation is affected by SMRAD51, like tumorigenesis. Centrosome and ploidy defects have also been observed in CHO cell lines mutated in XRCC2 or XRCC3, two Rad51 paralogs (Griffin et al., 2000) , suggesting that the HR pathway is involved in these phenomena. However, the impact of XRCC2 and XRCC3 on tumorigenesis has not been measured. Since centrosome duplication defect can result in aneuploidy, it is often associated with tumor development (Lengauer et al., 1998; Pihan et al., 1998) . Taken together, these data support the interpretation that SMRAD51 stimulates tumorigenesis via HR inhibition. It can be proposed that the defect in the RAD51 recombination pathway alters DNA repair accuracy leading to mutagenesis, genome rearrangements, and aneuploidy.
The experiments presented here were performed in the hamster CHO cell line defective in the p53 pathway and thus presenting tumor predisposition. Remarkably, the expression of the dominant-negative SMRAD51 does not tolerate a wild-type p53 background (data to be published), suggesting that the essential role of RAD51 is dependent on p53 status. In line with this, inactivation of p53 partially rescued the death phenotype of the null rad51 mice, the embryonic lethality occurring a few days later in the double null rad51
À/À mutant compared to the single rad51 À/À null mutant (Lim and Hasty, 1996) . Since the inhibition of the RAD51-recombination pathway is viable but can increase tumorigenesis in a mutant p53 background, this implies that p53 mutation should pre-exist to allow RAD51 alteration. Indeed, alteration of the RAD51-recombination pathway in a mutant p53 background provides additional ways to generate aneuploidy and should thus result in higher cancer risks. Decreases in RAD51 expression and rad51 mutations in tumors have been reported, but they do not permit direct demonstration of the tumor protective role of RAD51 . Interestingly, the rad51-135c mutation also shows a stimulatory effect on breast cancer risks in a mutant brca2 background (Levy-Lahad et al., 2001) . Similarly, we show here that the inhibition of the RAD51-recombination pathway increases tumorigenesis in a mutant p53 background. A direct implication of the recombination machinery in tumor protection remained to be established. The data presented here constitute the first direct evidence of the role of RAD51 during tumor progression. However, these data suggest that RAD51 alteration does not participate in tumor initiation but, in our view, in tumor progression in a later step, following the inactivation of other pathways such as the p53 pathway. According to this view, RAD51 would act as a tumor repressor rather than a tumor suppressor.
Materials and methods
DNA manipulations
All DNA manipulations were performed as described (Sambrook et al., 1989; Ausubel et al., 1999) .
Cells and injection
Cells were cultured at 371C with 5% CO 2 in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mm glutamine, 200 IU/ml penicillin, 200 mg/ml streptomycin, and 2.5 mg/ml puromycin (Calbiochem). Cell proliferation was determined for each line by plating 7 Â 10 3 cells and counting over several days. Each point corresponds to triplicate measurements. Before injection, cells were trypsinized, washed twice with PBS, and counted in the presence of trypan blue. Cells 5 Â 10 6 suspended in 200 ml PBS were used for subcutaneous injection in 4-week-old female nude mice (ico: Swiss-nu/nu, Iffa Credo). All animal procedures were carried out in accordance with French regulations.
Western blot analysis
All extract preparation steps were performed at 41C. After washing with PBS, cells were suspended in lysis buffer A (25 mm Tris pH 7.5, 5 mm EDTA, 600 mm NaCl, 1 mm DTT, 0.1% NP40, 5 mg/ml leupeptin, 2 mm pepstatin, 1 mm PMSF) and incubated for 30 min on ice. Extracts were centrifuged for 30 min at 15 000/g, the supernatant was recovered and protein concentration was determined using the Biorad Protein Assay (Biorad). A measure of 50 mg/well of the boiled samples were loaded on a 10% polyacrylamide gel for electrophoresis in the presence of SDS. After migration, the proteins were electrotransferred to a nitrocellulose membrane and probed with specific anti-human Rad51 antibodies (Oncogene Research). Standard procedures were used for the electrophoresis, transfer and Western blotting. Antibodies were visualized using the ECL detection kit (Amersham).
Centrosomes
Cells were plated, synchronized and then exposed to 6 Gy of gamma-radiation ( 137 Cs, 2.5 Gy/min), 3 h after the thymidine block release (late S/G2 phase). At 3-6 h after irradiation, and at the corresponding times for unirradiated cells, cells were fixed in methanol for 15 min at À201C. After three washes in PBS, saturation in fetal calf serum for 15 min, and three washes in PBS centrosomes were stained with g-tubulin antibody (Sigma) diluted 1/1000 in 1% BSA and 0.05% Tween for 1 h at 371C. Cells were washed three times in PBS, 0.05% Tween, and incubated with a rabbit antibody coupled with cyanine 2 (Jackson), diluted 1/400. After three washes in PBS, 0.05% Tween, cells were incubated with DAPI (5 mg/ml).
Chromosomes
Cells were incubated with colchicine (0.06 mg/ml) for 3 h. Cells were collected and incubated in KCl (12.5 mm) and human serum (1/7 v/v) for 20 min at 371C. Cells fixed overnight in methanol/acetic acid (3/1 v/v) were washed three times in methanol/acetic acid, spread on cold microscope slides, and stained with 3% Giemsa in 1.5% phosphate buffer pH 6.7. Metaphases were analysed by microscopy.
